Dupixent Sales Drive Sanofi Collaboration Revenue
Sanofi collaboration revenue rose 50.4% YoY to $2.17B in Q2 FY2026, supported by a 38% YoY surge in global net sales of Dupixent to $6.00B.
At the archive date, REGENERON PHARMACEUTICALS, INC. was expected to release its Q3 2026 10-Q filing on October 26, 2026. Last quarter: In Q2 FY2026, Regeneron generated $4.29B in revenue, up 16.7% YoY, driven by strong Dupixent collaboration revenue and EYLEA HD growth, despite persistent competitive pressures on legacy EYLEA and a 6.8% decline in net income to $1.30B.
EPS Estimate
$16.17
Revenue Estimate
$4.63B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the REGN page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Sanofi collaboration revenue rose 50.4% YoY to $2.17B in Q2 FY2026, supported by a 38% YoY surge in global net sales of Dupixent to $6.00B.
EYLEA HD U.S. net sales increased 52% YoY to $596.3M, partially offsetting a 45% YoY decline in legacy U.S. EYLEA sales ($412.2M) caused by market transition to EYLEA HD and increasing biosimilar competition.
In April 2026, Regeneron finalized agreements with the U.S. government establishing Most-Favored-Nation Pricing for select Medicaid products, joining TrumpRx.gov, offering Otarmeni free of charge, and securing tariff protection through January 2029 tied to domestic R&D and manufacturing investments.
Revenue
$4.29B
+16.73% YoY
EPS (Diluted)
$12.23
-4.53% YoY
Operating Income
$1.29B
+19.82% YoY
Add REGN to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.